Characterization and functional role of voltage gated cation conductances in the glucagon-like peptide-1 secreting GLUTag cell line.
Glucagon-like peptide-1 (GLP-1) is released from intestinal L-cells in response to nutrient ingestion. It is currently under therapeutic evaluation because it enhances insulin secretion in type 2 diabetes. Previous studies using the GLP-1 secreting cell line GLUTag have shown that the cells are electrically active, and that the action potential frequency is regulated by nutrients. In this study we characterize voltage gated currents underlying this electrical activity and correlate the electrophysiological findings with gene expression determined by microarrays. Whole cell voltage clamp experiments designed to separate different ionic components revealed rapidly inactivating sodium currents sensitive to tetrodotoxin, calcium currents sensitive to nifedipine and omega-conotoxin GVIA, and sustained as well as rapidly inactivating potassium currents, which were sensitive to TEA and 4-AP, respectively. In perforated patch experiments we also observed hyperpolarization-activated currents which were inhibited by ZD7288. The amplitude of the sodium current was approximately 10 times that of the other depolarizing currents and tetrodotoxin abolished action potential firing. In secretion experiments, however, nifedipine, but not tetrodotoxin, omega-conotoxin GVIA or ZD7288, inhibited glucose-induced GLP-1 release. Consistent with this finding, the intracellular Ca2+ response to glucose was impaired by nifedipine but not by tetrodotoxin. Thus, in GLUTag cells, GLP-1 release is not dependent on the firing of Na+-carrying action potentials but requires membrane depolarization and Ca2+ entry through L-type Ca2+ channels. Understanding the characteristics of the currents and the molecular identification of the underlying channels in GLP-1 secreting cells might facilitate the development of agents to enhance GLP-1 secretion in vivo.
Reimann
F
F
Cambridge Institute for Medical Research, University of Cambridge, Department of Clinical Biochemistry, Wellcome Trust/MRC Building, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2XY, UK. fr222@cam.ac.uk
Maziarz
M
M
Flock
G
G
Habib
A M
AM
Drucker
D J
DJ
Gribble
F M
FM
D000818:Animals; D002118:Calcium / Q000378:metabolism*; D002414:Cations, Monovalent; D002460:Cell Line; D004553:Electric Conductivity; D019858:Enteroendocrine Cells / Q000502:physiology*; D005934:Glucagon / Q000378:metabolism*; D052216:Glucagon-Like Peptide 1; D015640:Ion Channel Gating / Q000502:physiology; D007473:Ion Channels / Q000032:analysis / Q000737:chemistry / Q000502:physiology*; D008564:Membrane Potentials / Q000502:physiology*; D051379:Mice; D010446:Peptide Fragments / Q000378:metabolism*; D011188:Potassium / Q000378:metabolism*; D011498:Protein Precursors / Q000378:metabolism*; D012964:Sodium / Q000378:metabolism*
D002414:Cations, Monovalent; D007473:Ion Channels; D010446:Peptide Fragments; D011498:Protein Precursors; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D012964:Sodium; D011188:Potassium; D002118:Calcium